Voyager begins Phase II of PD gene therapy VY-AADC

Voyager Therapeutics Inc. (NASDAQ:VYGR) started the Phase II RESTORE-1 trial of gene therapy VY-AADC to treat Parkinson's disease patients with motor fluctuations that are refractory to medical management.

The double-blind, U.S. trial is slated to enroll about 42 patients to receive a one-time administration of VY-AADC or placebo surgery. The trial's primary endpoint will evaluate the change from baseline in "on" time without troublesome dyskinesia as measured by self-reported patient diary at 12 months...